Business
CELTIC THERAPEUTICS AND BELLUS HEALTH INITIATE CONFIRMATORY PHASE III CLINICAL STUDY FOR KIACTA?, A DRUG CANDIDATE FOR THE TREATMENT OF AA AMYLOIDOSIS
CELTIC THERAPEUTICS AND BELLUS HEALTH INITIATE CONFIRMATORY PHASE III CLINICAL STUDY FOR KIACTA¿,...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\n Dec. 15, 2010 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nLAVAL, QC, and NEW YORK, Dec. 15 /CNW Telbec/ - BELLUS Health Inc. (TSX:\n BLU) and Celtic Therapeutics announced today that a global confirmatory\n phase III clinical study was initiated on December 14, 2010 for KIACTA™\n (eprodisate). KIACTA™ is a drug candidate being developed for the\n treatment of AA amyloidosis, a life-threatening orphan disease that\n occurs in patients with long-lasting inflammatory conditions, most\n commonly due to rheumatoid arthritis. The study is designed to confirm\n the safety and efficacy of KIACTA™ in preventing renal function decline\n in patients with AA amyloidosis.\n\n\n"KIACTA™ has the potential to offer a much awaited treatment to patients\n with AA amyloidosis, a devastating disease affecting an estimated\n 50,000 patients in the United States, Europe and Japan, for which there\n is currently no specific treatment available," said Dr. Peter B. Corr,\n Co-Founder and General Partner of Celtic Therapeutics. "In its initial\n phase III clinical study, KIACTA™ reduced the risk of renal decline or\n mortality by 42% (Cox proportional hazards regression model, p=0.025)\n as compared to placebo over a two-year period, and showed an excellent\n safety profile. KIACTA™ also continues to be safe and well tolerated\n upon chronic administration, with some patients exposed to the compound\n for more than eight years in the ...